Phase 2 human clinical trials of an antigen against parasitic infections caused by hookworms have shown it to be effective in limiting the intensity of infection, paving the way for vaccine development.
An international team of scientists from George Washington University, the University of Nottingham, and Baylor College of Medicine has been collaborating for years to find treatments for diseases caused by hookworms. they identified american assassin Glutathione S-transferase-1 (already-GST-1) is used as a key enzymatic step in hookworm blood feeding and as a primary target for vaccine development.
using alreadyThe research team utilized the GST-1 antigen to develop a human hookworm infection (CHHI) model to evaluate the impact of hookworm vaccine candidates on infection. Results from 39 participants who volunteered for the trial showed a reduction in the intensity of infection and were published today in The Lancet Infection Sciences.
hookworm american assassin It occurs in tropical climates and enters the body through the skin, usually when stepped on barefoot. The insect then sheds its skin, which is thought to trigger a distracting immune response. If left untreated, severe infections can lead to anemia and long-term discomfort and disability.
Apart from malaria, hookworm disease is one of the most important parasitic infections in terms of global disease burden. An estimated 113 million people have been infected worldwide, with the highest concentrations in Africa and Southeast Asia, although some estimates put the actual number of infections at more than 400 million.
already-GST-1 is a potential vaccine antigen that scientists have long believed to induce neutralizing antibodies against a natural enzyme that plays an important function in the host blood digestive pathway of adult hookworms. Vaccination already-GST-1 is intended to prevent the development of nematodes or cause death of the parasites, both of which reduce disease symptoms and block infection.
Professor David Diemert from George Washington University, who led the trial, said: “This work is an important step in the development of an effective hookworm vaccine, which will be an essential tool to prevent anemia and improve the health of vulnerable populations.”
David Pritchard, emeritus professor of parasite immunology at the University of Nottingham’s School of Pharmacy, led the project in the UK and in 2006 tested the effects of these parasites on humans by putting 50 hookworms in their arms. This study established the necessary safety and regulatory standards to enable the conduct of this human infection study.
This new research is an important step toward developing an effective vaccine against hookworm disease, which my colleagues and I have been working on for more than 40 years. In the 1980s, our research group began studying the immunology of gangrene (american assassin/ hookworm disease). In particular, we were interested in explaining why hookworm infections accumulate throughout life in the tropics and quickly recur after effective deworming chemotherapy. Fast forward to 2026, and glutathione S-transferase was shown to vaccinate against infections in human challenge tests using PNG isolates. American murderer. ”
David Pritchard, Emeritus Professor of Parasitology and Immunology, University of Nottingham
sauce:
Reference magazines:
DiRosato, C.K. Others. (2026). Using a US control human infection model, we co-administered Na-GST-1 adsorbed to alhydrogel with various Toll-like receptor agonists to hookworm-free adults. Phase 2, double-blind, randomized controlled trial. lancet infection. DOI: 10.1016/s1473-3099(26)00018-6. https://www.sciencedirect.com/science/article/abs/pii/S1473309926000186?dgcid=author
